At a glance
ClinicalIndex Comparison RecordPhase 2Unknown· 155 target
Drug / intervention
JMT101 +1 moredrug
Likely dose
JMT101 6 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Open Label, Multi-center Study to Assess the Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
In Brief
A Phase 2 clinical trial evaluating JMT101 and Osimertinib Mesylate Tablets for Locally Advanced or Metastatic Non-Small Cell Lung Cancer and EGFR Exon20 Insertion Mutations. Targeting 155 participants.
Detailed Summary
This study is a phase II, open label, multi-center study to evaluate the efficacy and safety of JMT101 combined with Osimertinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLocally Advanced or Metastatic Non-Small Cell Lung Cancer, EGFR Exon20 Insertion Mutations
Countries--
CollaboratorsCSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Timeline
Phase 2UnknownOverdue
20222023202420252026
Enrollment StartNov 2021
First PostedNov 2021
Primary CompletionSep 2023
Study CompletionSep 2024
TodayJul 2026
First PostedNov 24, 2021
Enrollment StartNov 20, 2021
Primary CompletionSep 30, 2023
Study CompletionSep 30, 2024
TodayJul 1, 2026
Enrollment to primary: 1.9 yearsPosted 4.6 years ago
Interventions
JMT101drug
JMT101, 6 mg/kg, IV infusion once every two weeks (one treatment cycle is 4 weeks).
Osimertinib Mesylate Tabletsdrug
Osimertinib, 160 mg, Oral administration once daily (one treatment cycle is 4 weeks).